News tagged ‘LungCancer’ clear
- Three Dana-Farber researchers, writing in a special issue of JAMA published today, make the case for policies and practices that give terminally ill patients more control over how and where they will die.
Tags: ColonCancer, EndOfLife, LungCancer
- Non-small cell lung cancer (NSCLC) in younger patients is a distinct disease, genetically and biologically, from NSCLC in older patients and may require a different treatment approach, Dana-Farber Cancer Institute scientists have found.
- In a span of five weeks beginning in late October, the U.S. Food and Drug Administration (FDA) gave approval to five new cancer drugs that proved effective in Dana-Farber-led clinical trials – and, in some cases, derive from basic research in Dana-Farber laboratories.
Tags: chemotherapy, BasicResearch, LungCancer, MultipleMyeloma, Sarcoma
- After identifying three different types of resistance to a promising investigational lung cancer drug, a team of researchers led by Dana-Farber Cancer Institute scientists say new targeted inhibitors and combinations are urgently needed to stay ahead of tumors’ constant and varied molecular shape-shifting.
- A study led by Pasi Jänne, MD, PhD, found that an experimental drug targeted to the resistance mutation is highly active in patients with EGFR-positive non-small cell lung cancer (NSCLC) when the disease progressed during treatment with front-line inhibitor drugs.
Tags: LungCancer, Genetics
- Small cell lung cancer – a disease for which no new drugs have been approved for many years – has shown itself vulnerable to an agent that disables part of tumor cells’ basic survival machinery, researchers at Dana-Farber Cancer Institute and the Massachusetts Institute of Technology reported.
Tags: Genomics, LungCancer
- Dana-Farber Cancer Institute and Astellas Pharma Inc. today announced a three-year collaboration to research and develop small molecule inhibitors of oncogenic K-Ras for the treatment of cancer, including lung cancer.
Tags: LungCancer, Partnerships
- The National Cancer Institute (NCI) has launched a new nationwide clinical trial to find out if two molecularly targeted drugs that have improved outcomes in advanced lung cancer can increase survival of patients with early-stage lung cancer that has been surgically removed.
Tags: LungCancer, TargetedTherapy